Canaccord Genuity Group Has Lowered Expectations for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS) had its price objective reduced by Canaccord Genuity Group from $31.00 to $28.00 in a research note released on Monday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $9.62 on Monday. The stock has a market capitalization of $500.53 million, a PE ratio of -12.18 and a beta of 0.74. The business has a fifty day moving average price of $7.90 and a two-hundred day moving average price of $10.33. GH Research has a fifty-two week low of $5.05 and a fifty-two week high of $14.99.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, equities analysts expect that GH Research will post -0.78 EPS for the current year.

Institutional Investors Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).